spacer
home > pmps > summer 2002 > providing global access to medicines - the role of manufacture and supply
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Providing Global Access to Medicines - The Role of Manufacture and Supply

A universally held objective is patient 'access' to health care interventions in general and medicines in particular - both patent-protected and generic. This represents a particular problem for patients in developing countries, many of whom (for a variety of reasons) do not currently have access. The barriers are multi-factorial: physical and health care infrastructures are often inadequate; financial resources are limited; military, social and political issues abound and country economic policies can have negative effects on health care provision. It is clear that these problems cannot be solved by initiatives in manufacture and supply (M&S), but at the same time some attention has been focused on whether local production, generic competition and technology transfer might make a significant contribution.

Unfortunately, much of the policy discussion within this area has been undertaken without an understanding or appreciation of modern pharmaceutical M&S. This article describes some of the key considerations, and highlights the access-related policy implications. There are five principal considerations, which largely apply equally to branded products and generics:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By David Webber, Fellow and Director of Economic Policy at the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) Dr David Webber is a Fellow and Director of Economic Policy at the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) in Geneva. David gained a degree in Biology and a PhD in Animal Physiology from London University, and then undertook postdoctoral research, which led to published papers on stomach function.
He joined Glaxo Pharmaceuticals in 1982, and was responsible for various marketing functions in the UK Operating Company, before assuming a role in the corporate strategy unit. In 1999, David was appointed Public Policy Director in the Corporate Policy and Public Affairs group. In 2000, David was seconded to IFPMA, where he is responsible for policy development in key areas for the industry.

spacer
David Webber
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ROUSSELOT INTRODUCES X-PURE® GelMA FOR TRANSLATIONAL MEDICINE

Irving, United States [03 June 2020] — Rousselot, a Darling Ingredients brand and the global leader of collagen-based solutions, takes on the digital challenge and introduces X-Pure® GelMA at Bio Digital 2020. The first GMP-ready range of gelatin methacryloyl (GelMA) biomaterials suitable for preclinical and clinical applications, X-Pure® GelMA is part of the X-Pure portfolio of ultra-pure gelatins and collagens, suitable for use as biomaterials in 3D bioprinting, tissue engineering, and regenerative medicine.
More info >>

White Papers

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

DiagnostikNet-BB

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement